Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab combined with TROP2 ADC for brain metastases from triple-negative breast cancer
ChiCTR2600133876Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab and sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Central nervous system objective response rate, Progression-free survival and 2 more. Started Dec 2024; status: completed.
02
Drugs
ivonescimabsacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600133876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133876.